Alnylam reports Q3 2026 revenue of $1.29B, 52% growth, driven by TTR franchise

Alnylam reported Q3 2026 global net product revenues of $1,292 million, up 52% year-over-year, driven by TTR franchise revenues of $1,150 million (59% growth). The company also expanded target enrollment for its nucresiran Phase 3 study to 2,250 patients and reported positive Phase 1 data for brezosiran in Huntington's disease.